I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...

By Dani Blum The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes ...

MoA International Fund earns a High Process Pillar rating. The main driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's average 10-year ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The most important driver of the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

Eli Lilly’s Mounjaro was added to the FDA’s drug shortage database in 2022, while Zepbound was added this April. Eli Lilly did not immediately respond to a request for comment from Quartz.